Island Pharmaceuticals Limited (ASX:ILA): Antiviral Programs Advance Across Marburg and Dengue Research

Aditi Sarkar

14 October 2026 08:18 PM AEDT

Island Pharmaceuticals Limited (ASX:ILA): Antiviral Programs Advance Across Marburg and Dengue Research

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Island is developing two antiviral programs, Galidesivir and ISLA-101, for different infectious diseases.
In February 2026, the company reported FDA feedback on the development pathway for Galidesivir in Marburg.
A June 2026 agreement expanded access to specialist research capabilities for Galidesivir studies.
Island announced in October 2026 that Galidesivir GMP manufacturing had commenced.
Its separate ISLA-101 program targets dengue and other mosquito-borne illnesses.

Island Pharmaceuticals Limited (ASX:ILA) develops clinical-stage antiviral treatments for infectious diseases, using a drug-repurposing approach and prior research to inform development. Its two programs address different viral threats: Galidesivir is being advanced for serious RNA-virus infections, including Marburg, while ISLA-101 is being investigated for dengue and related mosquito-borne diseases. Throughout 2026, the company reported developments involving regulatory engagement, specialist research arrangements and manufacturing preparation.

Galidesivir Development and Regulatory Engagement

Galidesivir is a nucleoside analogue designed to interfere with viral RNA synthesis. According to Island Pharmaceuticals (ASX:ILA), the compound has demonstrated activity against more than 20 RNA viruses in earlier research. Such findings do not establish clinical effectiveness or regulatory approval for every virus identified. Its current program includes work directed towards Marburg, a disease for which specialised testing and regulatory procedures are needed.

On 4 February 2026, Island Pharmaceuticals (ASX:ILA) reported feedback from the US Food and Drug Administration concerning development under the Animal Rule. The company outlined a two-stage sequence involving dose optimisation and pharmacokinetic work before a pivotal confirmatory study. This approach reflects the difficulty of evaluating treatments for rare, life-threatening infections using conventional human efficacy trials. Regulatory discussions establish development requirements; they are not equivalent to product approval.

Research Arrangements and Manufacturing

In June 2026, the company announced expanded research support for a proposed Galidesivir study involving the Marburg virus. The planned work was designed to assess treatment timing, dose regimens, survival and viral-load measurements in non-human primates. These are research endpoints rather than demonstrated clinical outcomes in patients.

Island Pharmaceuticals (ASX:ILA) also continued preparatory work on the supply of Galidesivir. Its official announcements list commencement of good manufacturing practice (GMP) manufacturing on 2 October 2026. Manufacturing readiness matters for producing material under controlled standards, but does not itself determine the results of development studies or regulatory review.

ISLA-101 and the Dengue Research Program

The separate ISLA-101 candidate is being developed for the prevention and treatment of dengue and potentially other mosquito-borne illnesses. The company describes activity against dengue serotypes and related flaviviruses in laboratory research, alongside clinical development through its PROTECT study. Laboratory findings, animal models and human investigations each answer different questions; evidence from one setting cannot automatically be generalised to another.

For Island Pharmaceuticals (ASX:ILA), the distinction between its programs is material. ISLA-101 is focused on dengue-related clinical research, whereas Galidesivir is currently associated with high-consequence viral threats and a specific US regulatory development pathway. Research expenditure, study design, regulatory correspondence and the availability of manufactured clinical material remain relevant operating considerations.

Financial and Development Considerations

The company reported cash and cash equivalents of $14.18m at 31 March 2026 and net cash used in operating activities of $1.3m during that quarter. These figures are specific to that reporting date and period, not a representation of its cash position in October. Development-stage pharmaceutical companies face costs for manufacturing, specialised studies, regulatory submissions and maintaining research programs before any potential commercial receipts.

Key Insights

Island Pharmaceuticals (ASX:ILA) entered the later part of 2026 with two distinct antiviral research programs. Galidesivir-related FDA engagement, research arrangements and manufacturing activity describe steps in its development process; ISLA-101 continues to address a different disease area. Results from planned studies, subsequent company disclosures and regulatory decisions will determine how these programs progress. None of the reported preparatory milestones, on its own, demonstrates marketing authorisation or established patient benefit.

FAQs

Q:What does Island Pharmaceuticals develop?

A:Clinical-stage antiviral candidates, principally Galidesivir and ISLA-101.

Q:What is the focus of the Galidesivir program?

A:Research into serious RNA-virus infections, including Marburg, alongside an FDA development pathway.

Q:What is ISLA-101 being developed for?

A:Dengue fever and potentially other mosquito-borne viral diseases.

Q:Does FDA development-pathway feedback mean Galidesivir is approved?

A:No. It concerns proposed evidence and study requirements, not marketing authorisation.

Q:What cash figure did Island disclose in 2026?

A:It reported $14.18m in cash and cash equivalents at 31 March 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.